243 related articles for article (PubMed ID: 12501882)
1. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
Perez-Marreno R; Chu FM; Gleason D; Loizides E; Wachs B; Tyler RC
Clin Ther; 2002 Nov; 24(11):1902-14. PubMed ID: 12501882
[TBL] [Abstract][Full Text] [Related]
2. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
Chu FM; Jayson M; Dineen MK; Perez R; Harkaway R; Tyler RC
J Urol; 2002 Sep; 168(3):1199-203. PubMed ID: 12187267
[TBL] [Abstract][Full Text] [Related]
3. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer.
Sartor O; Dineen MK; Perez-Marreno R; Chu FM; Carron GJ; Tyler RC
Urology; 2003 Aug; 62(2):319-23. PubMed ID: 12893343
[TBL] [Abstract][Full Text] [Related]
4. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
[TBL] [Abstract][Full Text] [Related]
5. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
[TBL] [Abstract][Full Text] [Related]
7. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
[TBL] [Abstract][Full Text] [Related]
8. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer.
Sharifi R; Knoll LD; Smith J; Kramolowsky E
Urology; 1998 Feb; 51(2):271-6. PubMed ID: 9495710
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan.
Suzuki K; Namiki M; Fujimoto T; Takabayashi N; Kudou K; Akaza H
Jpn J Clin Oncol; 2015 Dec; 45(12):1168-74. PubMed ID: 26486824
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer.
Spitz A; Young JM; Larsen L; Mattia-Goldberg C; Donnelly J; Chwalisz K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):93-9. PubMed ID: 22025196
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45 mg 6-month depot formulations in patients with prostate cancer.
Mostafa NM; Chwalisz K; Larsen L; Mattia-Goldberg C; Spitz A; Pradhan RS
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):270-5. PubMed ID: 27128832
[TBL] [Abstract][Full Text] [Related]
12. A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.
Shore N; Mincik I; DeGuenther M; Student V; Jievaltas M; Patockova J; Simpson K; Hu CH; Huang ST; Li Y; Lee Y; Chien B; Mao J
World J Urol; 2020 Jan; 38(1):111-119. PubMed ID: 30941562
[TBL] [Abstract][Full Text] [Related]
13. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
14. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
Crawford ED; Moul JW; Sartor O; Shore ND
Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
[TBL] [Abstract][Full Text] [Related]
16. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer.
Sharifi R; Browneller R;
J Urol; 2002 Sep; 168(3):1001-4. PubMed ID: 12187208
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.
Yu EY; Getzenberg RH; Coss CC; Gittelman MM; Keane T; Tutrone R; Belkoff L; Given R; Bass J; Chu F; Gambla M; Gaylis F; Bailen J; Hancock ML; Smith J; Dalton JT; Steiner MS
Eur Urol; 2015 Feb; 67(2):334-41. PubMed ID: 24968970
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
19. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Koh Y; Kawashima A; Ujike T; Nagahara A; Fujita K; Kiuchi H; Imamura R; Miyagawa Y; Nonomura N; Uemura M
Anticancer Drugs; 2020 Nov; 31(10):1099-1102. PubMed ID: 32804697
[TBL] [Abstract][Full Text] [Related]
20. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
